- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04334031
Deployment o the Multidisciplinary Prospective Cohort Imminent (IMMINeNT)
Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions.
Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment.
These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David Launay, MD,PhD
- Phone Number: +33 03 20 44 42 95
- Email: david.launay@chru-lille.fr
Study Locations
-
-
-
Lille, France, 59037
- Recruiting
- Hop Claude Huriez Chu Lille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology)
- Social insured
- Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures.
Exclusion Criteria:
- Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system.
- Pregnant or breastfeeding woman
- Persons deprived of liberty
- Protected minors or adults
- Persons who have refused or are incapable of giving informed consent
- Persons in Emergency Situations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMMINeNT cohort
|
Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit.
For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of SLEDAI for lupus
Time Frame: once a year for 10 years
|
for lupus:Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) The SLEDAI score calculator consists of a list of 24 items, 16 clinical and 8 laboratory results.The total score falls between 0 and 105, with higher scores representing increased disease activity.
|
once a year for 10 years
|
Change of Medsger score
Time Frame: once a year for 10 years
|
Medsger Score estimates disease involvement of each organ (heart, vessels, skin, brain, kidney, gut, muscle, joint and loss of weight,) ranging from 0 to 4 (0: normal, 1: mild, 2: moderate, 3: severe, 4: terminal).
The score ranges from 0 to 36 points.A higher score means a worse outcome.
|
once a year for 10 years
|
Change of EDSS for multiple sclerosis
Time Frame: once a year for 10 years
|
for multiple sclerosis:Expanded Disability Status Scale (EDSS) The EDSS quantifies disability in eight Functional Systems (FS) by assigning a Functional System Score (FSS) in each of these functional systems EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory.
EDSS steps 5.0 to 9.5 are defined by the impairment to ambulation.EDSS score is a specific multiple sclerosis scale, from 0 (normal neurological status) to 10 (death kinked to sclerosis).
|
once a year for 10 years
|
Change of BASDAI for psoriatic arthristis
Time Frame: once a year for 10 years
|
For psoriatic arthritis:Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) he BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS: Fatigue/Spinal pain/Arthralgia (joint pain) or swelling/Enthesitis, or inflammation of tendons and ligaments (areas of localized tenderness where connective tissues insert into bone)/Morning stiffness duration/Morning stiffness severity.
|
once a year for 10 years
|
Change of Longhurst criteria for hereditary angioedema
Time Frame: once a year for 10 years
|
for hereditary angioedema: Longhurst criteria
|
once a year for 10 years
|
Change of number of flares for atopic dermatitis
Time Frame: once a year for 10 years
|
There is no validated score for atopic dermatitis and severe asthma.For atopic dermatitis, disease activity will be assessed by the number of flares per month with any affected body surface area (ACS) and the number of flares with body surface area >20%.
|
once a year for 10 years
|
Change of number of exacerbations for severe asthma
Time Frame: once a year for 10 years
|
For severe asthma, disease activity will be assessed by the number of exacerbations per month, where an exacerbation is defined as a loss of control resulting in an increase in beta2mimetic intake (>2 times daily compared to usual) and/or asthma-related limitation of daily activity and/or peak-flow change >30% from baseline on at least 2 consecutive days)
|
once a year for 10 years
|
Change of 12-Item Short-Form Health Survey (SF-12) - quality of life scale
Time Frame: once a year for 10 years
|
Health-related Quality of Life variable measured using the Short Form Health Survey (SF12): 12-item self-report that assesses physical and mental health related quality of life.
Results are expressed in terms of two meta-scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
The PCS and MCS scores have a range of 0 to 100 and were designed to have a mean score of 50.
Higher scores indicate better physical functioning.
|
once a year for 10 years
|
number of participant with severe infectious events
Time Frame: once a year for 10 years
|
once a year for 10 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Launay, MD,PhD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Skin Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Hypersensitivity, Immediate
- Eye Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Uveitis, Anterior
- Panuveitis
- Uveitis
- Uveal Diseases
- Vasculitis
- Hereditary Autoinflammatory Diseases
- Skin Diseases, Genetic
- Skin Diseases, Vascular
- Skin Diseases, Papulosquamous
- Hypersensitivity
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Spondylarthritis
- Spondylitis
- Psoriasis
- Urticaria
- Multiple Sclerosis
- Sclerosis
- Behcet Syndrome
- Dermatitis
- Scleroderma, Systemic
- Arthritis, Psoriatic
- Angioedema
Other Study ID Numbers
- 2018_82
- 2019-A01309-48 (Other Identifier: ID-RCB number,ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Biobanking with genetic analysis
-
University Hospital, LilleRecruiting
-
Maastricht University Medical CenterRecruiting
-
University Hospital, CaenCompleted
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLynch Syndrome | Relatives | Endometrial Carcinoma | Endometrial AdenocarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8United States
-
GWT-TUD GmbHTerminatedAcute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)France, Germany
-
University of Milano BicoccaRecruiting
-
University Hospital, MontpellierTerminated
-
CHU de ReimsCompletedProliferative Diabetic RetinopathyFrance
-
Stanford UniversityTerminatedRectal Cancer | Colon Cancer | Colonic Neoplasms | Anal CancerUnited States